Trial Profile
A Phase 2a Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK1265744 Monotherapy Versus Placebo in HIV-1 Infected Adults (ITZ112929).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; ViiV Healthcare
- 01 Sep 2013 Results published in HIV Clinical Trials.
- 22 Sep 2009 Actual patient number (9) added as reported by ClinicalTrials.gov.
- 22 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.